Tilray TLRY stock analysis and why TLRY stock will likely drop lower

COVID-19 mRNA vaccines have sparked interest in the potential of mRNA technology, but they have also put producers at the centre of licensing lawsuits. Credit:

Santhera plan to repay its debt of CHF 29m ($33.8m) to Highbridge Capital and fund the pre-commercialization and launch of vamorolone in Europe. Image Credit: